Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 254

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Insulin Resistance and Dysregulation of Tryptophan–Kynurenine and Kynurenine–Nicotinamide Adenine Dinucleotide Metabolic Pathways

Open access
Oxenkrug, Gregory·2013·Molecular Neurobiology
DOI 10.1007/s12035-013-8497-4
Open this paper in CoChat — free account

Abstract

Insulin resistance (IR) underlines aging and aging-associated medical (diabetes, obesity, dyslipidemia, hypertension) and psychiatric (depression, cognitive decline) disorders. Molecular mechanisms of IR in genetically or metabolically predisposed individuals remain uncertain. Current review of the literature and our data presents the evidences that dysregulation of tryptophan (TRP)–kynurenine (KYN) and KYN–nicotinamide adenine dinucleotide (NAD) metabolic pathways is one of the mechanisms of IR. The first and rate-limiting step of TRP–KYN pathway is regulated by enzymes inducible by pro-inflammatory factors and/or stress hormones. The key enzymes of KYN–NAD pathway require pyridoxal-5-phosphate (P5P), an active form of vitamin B6, as a cofactor. Deficiency of P5P diverts KYN–NAD metabolism from production of NAD to the excessive formation of xanthurenic acid (XA). Human and experimental studies suggested that XA and some other KYN metabolites might impair production, release, and biological activity of insulin. We propose that one of the mechanisms of IR is inflammation- and/or stress-induced upregulation of TRP–KYN metabolism in combination with P5P deficiency-induced diversion of KYN–NAD metabolism towards formation of XA and other KYN derivatives affecting insulin activity. Monitoring of KYN/P5P status and formation of XA might help to identify subjects at risk for IR. Pharmacological regulation of the TRP–KYN and KYN–NAD pathways and maintaining of adequate vitamin B6 status might contribute to prevention and treatment of IR in conditions associated with inflammation/stress-induced excessive production of KYN and deficiency of vitamin B6, e.g., type 2 diabetes, obesity, cardiovascular diseases, aging, menopause, pregnancy, and hepatitis C virus infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12035-013-8497-4

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 106

  1. Esposito K, Giugliano D (2004) The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis 14:228–232 · DOI · Paper page
  2. Oxenkrug GF (2011) Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated medical and psychiatric disorders. J Neural Transm 118:75–85 · DOI
  3. Oxenkrug GF (2007) Genetic and hormonal regulation of the kynurenine pathway of tryptophan metabolism: new target for clinical intervention in vascular dementia, depression and aging. Ann N Y Acad Sci 1122:35–49 · DOI
  4. Takahashi H, Kaihara M, Price JM (1956) The conversion of kynurenic acid to quinaldic acid by human and rats. J Biol Chem 223:705–708 · doi:10.1016/s0021-9258(18)65070-7
  5. Ogasawara N, Hagino Y, Kotake Y (1962) Kynurenine-transaminase, kynureninase and the increase of xanthurenic acid excretion. J Biochem 52:162–166 · DOI
  6. Takahashi H, Price JM (1956) Dehydroxylation of xanthurenic acid to 8-hydroxyquinaldic acid. J Biol Chem 233:150–153 · doi:10.1016/s0021-9258(19)68045-2
  7. van de Kamp JL, Smolen A (1995) Response of kynurenine pathway enzymes to pregnancy and dietary level of vitamin B-6. Pharmacol Biochem Behav 51:753–784 · doi:10.1016/0091-3057(95)00026-s
  8. Bender DA, Njagi EN, Danielian PS (1990) Tryptophan metabolism in vitamin B6-deficient mice. Br J Nutr 63:27–36 · DOI
  9. Guilarte TR, Wagner HN Jr (1987) Increased concentrations of the endogenous tryptophan metabolite 3-hydroxykynurenine (3-HK) were measured in the brains of vitamin B6 deficient neonatal rats. J Neurochem 49:1918–1926 · doi:10.1111/j.1471-4159.1987.tb02455.x
  10. Midttun O, Ulvik A, Pedersen E, Ebbing M, Bleie O et al (2011) Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. J Nutr 141:611–617 · DOI
  11. Kimoto M, Ogawa T, Tokushima SK (1991) Accumulation of 3-hydroxy-l-kynurenine sulfate and ethanolamine in urine of the rat injected with 1-aminoproline. J Exp Med 38:37–44
  12. Rogers KS, Evangelista SJ (1985) 3-Hydroxykynurenine, 3-hydroxyanthranilic acid, and o-aminophenol inhibit leucine-stimulated insulin release from rat pancreatic islets. Proc Soc Exp Biol Med 178:275–278 · DOI
  13. Sarkar SA, Wong R, Hackl SI, Moua O, Gill RC et al (2007) Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. Diabetes 56:72–79 · DOI
  14. Rudzite V, Fuchs D, Kalnins U, Jurika E, Silava A et al (2003) Prognostic value of tryptophan load test followed by serum kynurenine determination. Its comparison with pyridoxal-5-phosphate, kynurenine, homocysteine and neopterin amounts. Adv Exp Med Biol 527:307–315 · doi:10.1007/978-1-4615-0135-0_34
  15. Yess N, Price JM, Brown RR, Swan PB, Linkswiler H (1964) Vitamin B6 depletion in man: urinary excretion of tryptophan metabolites. J Nutr 84:229–236 · DOI
  16. Tsubouchi R, Izuta S, Shibata Y (1989) Kynurenine metabolism and xanthurenic acid formation in vitamin B6-deficient rat after tryptophan injection. J Nutr Sci Vitaminol (Tokyo) 35:111–122 · doi:10.3177/jnsv.35.111
  17. Okamoto H (2003) Recent advances in physiological and pathological significance of tryptophan-NAD+ metabolites: lessons from insulin-producing pancreatic beta-cells. Adv Exp Med Biol 527:243–252 · DOI
  18. Cho-Chung YS, Pitot HC (1967) Feedback control of liver tryptophan pyrrolase. J Biol Chem 242:1192 · DOI
  19. Shibata Y, Ohta T, Nakatsuka M, Ishizu H, Matsuda Y et al (1996) Taurine and kynureninase. Adv Exp Med Biol 40:55–58 · doi:10.1007/978-1-4899-0182-8_6
  20. Takeuchi F, Tsubouchi R, Shibata Y (1985) Effect of tryptophan metabolites on the activities of rat liver pyridoxal kinase and pyridoxamine 5-phosphate oxidase in vitro. Biochem J 227:537–544 · doi:10.1042/bj2270537
  21. Murakoshi M, Tanimoto M, Gohda T, Hagiwara S, Ohara I et al (2009) Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. Diabetes Res Clin Pract 83:183–189 · DOI
  22. Hattori M, Kotake Y, Kotake Y (1984) Studies on the urinary excretion of xanthurenic acid in diabetics. Acta Vitaminol Enzymol 6:221–228
  23. Munipally PK, Agraharm SG, Valavala VK, Gundae S, Turlapati NR (2011) Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Arch Physiol Biochem 117(5):254–258 · DOI
  24. Kotaki Y, Ueda T, Mori T, Igaki S, Hattori M (1975) Abnormal tryptophan metabolism and experimental diabetes by xanthurenic acid (XA). Acta Vitaminol Enzymol 29:236–239
  25. Meyramov G, Korchin V, Kocheryzkina N (1984) Diabetogenic activity of xanturenic acid determined by its chelating properties? Acta Vitaminol Enzymol 6:221–228
  26. Ikeda S, Kotake Y (1986) Urinary excretion of xanthurenic acid and zinc in diabetes: (3). Occurrence of xanthurenic acid-Zn2+ complex in urine of diabetic patients and of experimentally-diabetic rats. Ital J Biochem 35:232–241
  27. Malina HZ, Richter C, Mehl M, Hess OM (2001) Pathological apoptosis by xanthurenic acid, a tryptophan metabolite: activation of cell caspases but not cytoskeleton breakdown. BMC Physiol 1:7–11 · DOI
  28. Wang Q, Chen J, Wang Y, Han X, Chen X (2012) Hepatitis C virus induced a novel apoptosis-like death of pancreatic beta cells through a caspase 3-dependent pathway. PLoS One 7:e38522. doi: 10.1371/journal.pone.0038522 · DOI
  29. Patterson AD, Bonzo JA, Li F, Krausz KW, Eichler GS, Aslam S, Tigno X, Weinstein JN, Hansen BC, Idle JR, Gonzalez FJ (2011) Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol Chem 286(22):19511–2233 · DOI
  30. Kuc D, Zgrajka W, Parada-Turska J, Urbanik-Sypniewska T, Turski WA (2008) Micromolar concentration of kynurenic acid in rat small intestine. Amino Acids 35:503–505 · DOI
  31. Lam CK, Chari M, Su BB, Cheung GW, Kokorovic A, Yang CS, Wang PY, Lai TY, Lam TK (2010) Activation of N-methyl-d-aspartate (NMDA) receptors in the dorsal vagal complex lowers glucose production. J Biol Chem 285(29):21913–21921 · DOI
  32. Noto Y, Okamoto H (1978) Inhibition by kynurenine metabolites of proinsulin synthesis in isolated pancreatic islets. Acta Diabetol Lat 15:273–282 · doi:10.1007/bf02590750
  33. Koopmans SJ, Ruis M, Dekker R, Korte M (2009) Surplus dietary tryptophan inhibits stress hormone kinetics and induces insulin resistance in pigs. Physiol Behav 98:402–410 · DOI
  34. Oxenkrug G (2010) Tryptophan–kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: serotonin hypothesis revisited 40 years later. Israel J Psychiatry 47:56–63
  35. Masiello P, Balestreri E, Bacciola D, Bergamini E (1987) Influence of experimental diabetes on brain levels of monoamine neurotransmitters and their precursor amino acids during tryptophan loading. Acta Diabetol Lat 24:43–50 · doi:10.1007/bf02732052
  36. Sucher R, Schroecksnadelb K, Weissb G, Margreitera R, Fuchs D, Brandacher G (2010) Neopterin, a prognostic marker in human malignancies. Cancer Lett 287:13–22 · DOI · Paper page
  37. Frick B, Schroecksnadel K, Neurauter G (2004) Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 37:684–687 · DOI · Paper page
  38. Fierabracci V, Novelli M, Ciccarone AM, Masiello P, Benzi L, Navalesi R, Bergamini E (1996) Effects of tryptophan load on amino acid metabolism in type 1 diabetic patients. Diabetes Metab 22:51–56
  39. Koenig P, Nagl C, Neurauter G, Schennach H, Brandacher G, Fuchs D (2010) Enhanced degradation of tryptophan in patients on hemodialysis. Clin Nephrol 74:465–470 · doi:10.5414/cnp74465
  40. Bertz L, Barani J, Gottsäter A, Nilsson PM, Mattiasson I, Lindblad B (2006) Are there differences of inflammatory bio-markers between diabetic and non-diabetic patients with critical limb ischemia? Int Angiol 25(4):370–377
  41. Allegri G, Zaccarin D, Ragazzi E, Froldi G, Bertazzo A, Costa CV (2003) Metabolism of tryptophan along the kynurenine pathway in alloxan diabetic rabbits. Adv Exp Med Biol 527:387–393 · DOI
  42. Manusadzhian VG, Kniazev IA, Vakhrusheva LL (1974) Mass spectrometric identification of xanthurenic acid in pre-diabetes. Vopr Med Khim 20:95–97
  43. Ledochowski M, Murr C, Widner B, Fuchs D (1999) Association between insulin resistance, body mass and neopterin concentrations. Clin Chim Acta 282:115–123 · DOI
  44. Schennach H, Murr C, Gächter E, Mayersbach P, Schönitzer D, Fuchs D (2002) Factors influencing serum neopterin concentrations in a population of blood donors. Clin Chem 48:643–645 · DOI
  45. Oxenkrug G, Tucker KL, Requintina P, Summergrad P (2011) Neopterin, a marker of interferon-gamma-inducible inflammation, correlates with pyridoxal-5′-phosphate, waist circumference, HDL-cholesterol, insulin resistance and mortality risk in adult Boston community dwellers of Puerto Rican origin. Am J Neuroprot Neuroregen 3:48–52 · DOI
  46. Shen J, Lai CQ, Mattei J, Ordovas JM, Tucker KL (2010) Association of vitamin B-6 status with inflammation, oxidative stress, and chronic inflammatory conditions: the Boston Puerto Rican Health Study. Am J Clin Nutr 91:337–342 · doi:10.3945/ajcn.2009.28571
  47. Könner AC, Brüning JC (2012) Selective insulin and leptin resistance in metabolic disorders. Cell Metab 16:144–152 · DOI · Paper page
  48. Szybiński Z, Szurkowska M (2001) Insulinemia—a marker of early diagnosis and control of efficacy of treatment of type II diabetes. Pol Arch Med Wewn 106:793–800
  49. Di Betta E, Mittempergher F, Terraroli C, Valloncini E, Salerni B (2007) Severe obesity and insulin resistance. Result obtained by the bilio-pancreatic diversion independently for an associated gastroresection or gastropreservation. Ann Ital Chir 78:201–207
  50. Watts SW, Shaw S, Burnett R, Dorrance AM (2011) Indoleamine 2,3-diooxygenase in periaortic fat: mechanisms of inhibition of contraction. Am J Physiol Heart Circ Physiol 301:H1236–H1247 · DOI
  51. Scarpellini E, Tack JJ (2012) Obesity and metabolic syndrome: an inflammatory condition. Dig Dis 30:148–153 · DOI
  52. Wolowczuk I, Hennart B, Leloire A, Bessede A, Soichot M et al (2012) Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone. Am J Physiol Regul Integr Comp Physiol 303:R135–R143 · DOI
  53. Brandacher G (2007) Chronic immune activation underlies morbid obesity: is IDO a key player? Curr Drug Metab 8:289–295 · DOI
  54. Aasheim ET, Hofsø D, Hjelmesaeth J, Birkeland KI, Bøhmer T (2008) Vitamin status in morbidly obese patients: a cross-sectional study. Am J Clin Nutr 87:362–369 · DOI · Paper page
  55. Lapin IP, Oxenkrug GF (1969) Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1:32–39
  56. Hayaishi O (1976) Properties and function of indoleamine 2,3-dioxygenase. J Biochem (Tokyo) 79:13P–21P · DOI
  57. Leonard BE (2005) The HPA and immune axes in stress: the involvement of the serotoninergic system. Eur Psychiatry 20:S302–S306 · DOI · Paper page
  58. Leonard BE, Myint A (2009) The psychoneuroimmunology of depression. Hum Psychopharmacol 24:165–175 · DOI · Paper page
  59. Oxenkrug GF, Requintina PJ (2003) Melatonin and jet lag syndrome: experimental model and clinical implications. CNS Spectrs 8:139–148 · DOI
  60. Oxenkrug G (2011) Interferon-gamma-inducible inflammation: contribution to aging and aging-associated psychiatric disorders. Aging Dis 2:474–486
  61. Oxenkrug G, Ratner R (2012) N-Acetylserotonin and aging-associated cognitive impairment and depression. Aging Dis 3:330–338
  62. Lapin IP (1973) Kynurenines as probable participants of depression. Pharmakopsychiatr Neuropsychopharmakol 6:273–279 · DOI
  63. Lapin IP (2003) Neurokynurenines (NEKY) as common neurochemical links of stress and anxiety. Adv Exp Med Biol 527:121–125 · DOI
  64. Merete C, Falcon LM, Tucker KL (2008) Vitamin B6 is associated with depressive symptomatology in Massachusetts elders. J Am Coll Nutr 27:421–427 · DOI
  65. Cazzulo CL, Mangoni A, Mascherpa G (1974) Tryptophan metabolism in affective psychoses. Br J Psychiatry 112:157–162 · doi:10.1192/bjp.112.483.157
  66. Demakakos P, Pierce MB, Hardy R (2010) Depressive symptoms and risk of type 2 diabetes in a national sample of middle-aged and older adults: the English longitudinal study of aging. Diabetes Care 33:792–797 · DOI
  67. Rustad JK, Musselman DL, Nemeroff CB (2011) The relationship of depression and diabetes: pathophysiological and treatment implications. Psychoneuroendocrinology 36:1276–1286 · DOI · Paper page
  68. Campayo A, de Jonge P, Roy JF, Saz P, de la Camara C et al (2010) Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. Am J Psychiatry 167:580–588 · DOI · Paper page
  69. Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE (1996) Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care 19:1097–1102 · DOI · Paper page
  70. Capuron L, Miller AH (2011) Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 130:226–238 · DOI · Paper page
  71. Oxenkrug G, Perianayagam M, Mikolich D, Requintina P, Shick L et al (2011) Interferon-gamma (+874) T/A genotypes and risk of IFN-alpha-induced depression. J Neural Transm 118:271–274 · DOI
  72. Oxenkrug GF, Requintina RJ, Mikolich DL, Ruthazer R, Viveiros K et al (2012) Neopterin as a marker of response to antiviral therapy in hepatitis C virus patients. Hepat Res Treat 2012:4, Article ID 619609
  73. Negro F, Alaei M (2009) Hepatitis C virus and type 2 diabetes. World J Gastroenterol 15:1537–1567 · DOI · Paper page
  74. Lin CC, Yin MC (2009) Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alpha and ribavirin. Clin Nutr 28:34–38 · DOI
  75. Knobler H, Schattner A (2005) TNF-alpha, chronic hepatitis C and diabetes: a novel triad. QJM 98:1–6 · DOI
  76. Brischetto R, Corno C, Amore MG, Leotta S, Pavone S et al (2003) Prevalence and significance of type-2 diabetes mellitus in chronic liver disease, correlated with hepatitis C virus. Ann Ital Med Int 18:31–36
  77. Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H (2008) Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int 28:355–362 · DOI
  78. Fuchs D, Norkrans G, Wejsta R, Reibnegger G, Weiss G et al (1982) Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b. Eur J Med 1:196–200
  79. Dilman VM (1971) Age-associated elevation of hypothalamic, threshold to feedback control, and its role in development, ageing, and disease. Lancet 1:1211–1219 · DOI
  80. Dilman VM, Lapin IP, Oxenkrug GF (1979) Serotonin and aging. In: Essman W (ed) Serotonin in health and disease, vol 5. Spectrum, London, pp 111–123
  81. Dilman VM, Anisimov VN (1980) Effect of treatment with phenformin, diphenylhydantoin or l-dopa on life span and tumour incidence in C3H/Sn mice. Gerontology 26:241–246 · DOI
  82. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA (2010) Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9:1057–1064 · DOI
  83. Barzilai N, Ferrucci L (2012) Insulin resistance and aging: a cause or a protective response? J Gerontol A Biol Sci Med Sci 67(12):1329–31 · DOI
  84. Gori AM, Sofi F, Corsi AM, Gazzini A, Sestini I et al (2006) Predictors of vitamin B6 and folate concentrations in older persons: the InCHIANTI study. Clin Chem 52:1318–1324 · DOI
  85. Selhub J, Troen A, Rosenberg IH (2010) B vitamins and the aging brain. Nutr Rev 68(Suppl 2):S112–S118 · DOI
  86. Spencer M, Jain A, Matteini A, Beamer B, Wang N-Y et al (2010) Serum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fat. J Gerontol A Biol Sci Med Sci 65:858–865 · DOI
  87. Niinisalo P, Raitala A, Pertovaara M, Oja SS, Lehtimäki T et al (2008) Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand J Clin Lab Invest 68:767–770 · DOI
  88. Fuchs D, Avanzas P, Arroyo-Espliguero R, Jenny M, Consuegra-Sanchez L, Kaski JC (2009) The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr Med Chem 16:4644–4653 · DOI
  89. Dilman VM (1994) Development, aging and disease: a new rationale for an intervention strategy. Harvard Acad Publ Chur, Switzerland, 1994
  90. Deguchi K, Kamada M, Irahara M, Maegawa M, Yamamoto S et al (20010) Postmenopausal changes in production of type 1 and type 2 cytokines and the effects of hormone replacement therapy. Menopause 8:266–273 · DOI
  91. Zoghby SM, Abdel-Tawab GA, Girgis LH, Moursi GE, Zeitoun R et al (1975) Functional capacity of the tryptophan-niacin pathway in the premenarchial phase and in the menopausal age. Am J Clin Nutr 28:4–9 · doi:10.1093/ajcn/28.1.4
  92. Schröcksnadel K, Widner B, Bergant A, Neurauter G, Schröcksnadel H, Fuchs D (2003) Tryptophan degradation during and after gestation. Adv Exp Med Biol 527:77–83 · DOI
  93. Kohl C, Walch T, Huber R, Kemmler G, Neurauter G et al (2005) Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. J Affect Disord 86:135–142 · DOI
  94. Bennink HJ, Schreurs WH (1975) Improvement of oral glucose tolerance in gestational diabetes by pyridoxine. Br Med J 3:13–15 · DOI
  95. Cady SG, Sono M (1991) 1-Methyl-dl-tryptophan, beta-(3-benzofuranyl)-dl-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-dl-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 291:326–333 · DOI · Paper page
  96. Ryu JK, Choi HB, McLarnon JG (2006) Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. Neuroscience 141:1835–1848 · DOI
  97. Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altshuler EL et al (2006) A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol 6:903–990 · DOI
  98. Branconnier R, Cole JO, Oxenkrug GF (1983) Cardiovascular effects of imipramine and bupropion and aged depressive patients. Psychopharmacol Bull 19:658–662
  99. Yu CJ, Zheng MF, Kuang CX, Huang WD, Yang Q (2010) Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2, 3-dioxygenase activity in vitro. J Alzheimers Dis 22:257–266 · DOI
  100. Li GS, Liu XH, Zhu H, Huang L, Liu YL, Ma CM, Qin C (2011) Berberine-improved visceral white adipose tissue insulin resistance associated with altered sterol regulatory element-binding proteins, liver × receptors, and peroxisome proliferator-activated receptors transcriptional programs in diabetic hamsters. Biol Pharm Bull 34:644–654 · DOI
  101. Zhao HL, Sui Y, Qiao CF, Yip KY, Leung RK et al (2012) Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes 61:933–943 · DOI
  102. Di Pierro F, Villanova N, Agostini F, Marzocchi R, Soverini V et al (2012) Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes 5:213–217 · DOI
  103. Navrotskaya VV, Oxenkrug G, Vorobyova LI, Summergrad P (2012) Berberine prolongs life span and stimulates locomotor activity of Drosophila melanogaster. Am J Plant Sci 3:1037–1040 · DOI
  104. Oxenkrug G, Navrotskaya V, Vorobyova L, Summergrad P (2012) Minocycline effect on life and health span of Drosophila melanogaster. Aging Dis 3:352–359
  105. Nachum-Biala Y, Troen AM (2012) B-vitamins for neuroprotection: narrowing the evidence gap. Biofactors 38:145–150. doi: 10.1002/biof.1006 · DOI
  106. Unoki-Kubota H, Yamagishi S, Takeuchi M, Bujo H, Saito Y (2010) Pyridoxamine dose-dependently decreased fasting insulin levels and improved insulin sensitivity in KK-A(y) mice, a model animal of obese, type 2 diabetes. Protein Pept Lett 17:1177–1181 · DOI

Cited by

See all 254

Metadata

Authors
Oxenkrug, G.
Venue
Molecular Neurobiology
Publisher
Springer Science and Business Media LLC
Published
2013-06-28
Volume
48
Issue
2
Pages
294-301
ISSN
  • 0893-7648 (ISSN-L)
  • 1559-1182
DOI
10.1007/s12035-013-8497-4
OpenAlex
W2029933945
Cited by
254
References
6
FWCI
3.03
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin Resistance and Dysregulation of Tryptophan–Kynurenine and Kynurenine–Nicotinamide Adenine Dinucleotide Metabolic Pathways. https://app.cochat.ai/papers/10.1007/s12035-013-8497-4
The paper
Oxenkrug, G. (2013). Insulin Resistance and Dysregulation of Tryptophan–Kynurenine and Kynurenine–Nicotinamide Adenine Dinucleotide Metabolic Pathways. Molecular Neurobiology. https://doi.org/10.1007/s12035-013-8497-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.